<DOC>
	<DOCNO>NCT00958724</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability neratinib combination vinorelbine maximum tolerate dose ( MTD ) determine previous study , determine low MTD two drug , well obtain preliminary information whether combination two drug effect solid tumor Japanese patient .</brief_summary>
	<brief_title>Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Confirmed pathologic diagnosis solid tumor curable available therapy neratinib plus vinorelbine reasonable treatment option . At least 1 measurable lesion define Response Evaluation Criteria Solid Tumors . Eastern Cooperative Oncology Group performance status 0 2 ( decline within 2 week sign informed consent form ) . Recovery clinically significant AEs relate prior therapy ( exclude alopecia ) . Left ventricular ejection fraction within study site 's limit normal . Screening laboratory value within follow parameter : Absolute neutrophil count : 1.5 × 109/L Platelet count : 100 × 109/L Hemoglobin : 9.0 g/dL Serum creatinine : 1.5 × upper limit normal Total bilirubin : 1.5 × ULN Aspartate aminotransferase alanine aminotransferase : 2.5 × ULN ( &lt; = 5 × ULN liver metastasis present ) . For woman childbearing potential , negative urine serum pregnancy test result study entry . All female male subject biologically capable child must agree commit use reliable method birth control duration study 28 day last dose test article . A subject biologically capable child use contraceptive sexual partner sterile use contraceptive . Prior treatment anthracyclines cumulative dose doxorubicin &gt; 400 mg/m2 , epirubicin &gt; 800 mg/m2 , equivalent dose anthracyclines derivative . Major surgery , chemotherapy , radical ( curative intent ) radiotherapy , investigational agent , cancer therapy within least 2 week treatment day 1 . Bone site disease . Active central nervous system metastasis , indicate clinical symptom , cerebral edema , and/or progressive growth . ( Subjects history CNS metastases cord compression allowable definitively treated anticonvulsant steroid least 4 week cycle 1 day 1 ) . QT ( QTc ) interval &gt; 0.47 know history QTc prolongation Torsades de Pointes . Presence clinically significant uncontrolled cardiac disease , include congestive heart failure ( New York Heart Association functional classification =2 ) , angina require treatment , myocardial infarction within past 12 month , clinically significant supraventricular arrhythmia ventricular arrhythmia require treatment intervention . Pregnant breastfeed woman . Significant chronic recent acute gastrointestinal disorder diarrhea major symptom ( eg , Crohn disease , malabsorption , grade 2 diarrhea etiology baseline ) . Inability unwillingness swallow tablet ( neratinib ) . Preexisting grade 2 great motor sensory neuropathy . Subject know human immunodeficiency virus seropositive and/or acute chronic hepatitis B infection ( hepatitis B surface antigen [ HBsAg ] positive ) hepatitis C infection ( antiHCV positive ) . History known hypersensitivity vinorelbine component . Any cancer within 5 year prior screen exception contralateral breast carcinoma , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin . Clinically significant ongoing recent infection within 2 week treatment day 1 . Evidence significant medical illness abnormal laboratory find would , investigator 's judgment , make subject inappropriate study . Examples include , limited , serious active infection ( ie , require intravenous antibiotic antiviral agent ) uncontrolled major seizure .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HKI-272</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Combination</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>